Pradaxa Approved for Treatment of Pulmonary Embolism and DVT

The FDA has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in certain patients, according to Boehringer Ingelheim Pharmaceuticals.